CAS 1223498-69-8: Roniciclib

Description:Roniciclib is a small molecule inhibitor primarily targeting cyclin-dependent kinases (CDKs), particularly CDK2 and CDK9, which play crucial roles in cell cycle regulation and transcription. This compound is being investigated for its potential therapeutic applications in various cancers, as it can disrupt the proliferation of cancer cells by inhibiting their growth and survival pathways. Roniciclib is characterized by its specific chemical structure, which includes a core that allows for selective binding to the ATP-binding site of CDKs. Its pharmacological profile suggests that it may exhibit both antitumor activity and a favorable safety margin, although detailed clinical data is necessary to fully understand its efficacy and side effects. The compound is typically administered in a controlled dosage regimen, and ongoing research aims to elucidate its mechanisms of action, optimal dosing strategies, and potential combination therapies with other anticancer agents. As with many investigational drugs, further studies are essential to establish its role in clinical practice.

Found 3 products.

Product data	Purity	Price range	Estimated delivery
Roniciclib REF: TM-T16784CAS: 1223498-69-8	98% - 98.84%	60.00 €~803.00 €	Wed 02 Apr 25
BAY 1000394 REF: TR-B127600CAS: 1223498-69-8	- - -	24,466.00 €	Tue 06 May 25
BAY 1000394 REF: 3D-YYB49869CAS: 1223498-69-8	Min. 95%	To inquire	Wed 07 May 25